JP7592029B2 - ヤヌスキナーゼ１の阻害のための新規化合物 - Google Patents

ヤヌスキナーゼ１の阻害のための新規化合物 Download PDF

Info

Publication number
JP7592029B2
JP7592029B2 JP2021570725A JP2021570725A JP7592029B2 JP 7592029 B2 JP7592029 B2 JP 7592029B2 JP 2021570725 A JP2021570725 A JP 2021570725A JP 2021570725 A JP2021570725 A JP 2021570725A JP 7592029 B2 JP7592029 B2 JP 7592029B2
Authority
JP
Japan
Prior art keywords
pyridin
pyrazol
imidazo
trifluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021570725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534510A5 (https=
JP2022534510A (ja
Inventor
サントシュ クマール ライ
マハデヴ バンドガー
サジド アリ
ヒマンシュ ライ
アモル パンドゥラン グンジャル
ラケシュ イスワール パティル
スリニヴァサ レディ バプラム
アニル クマール
Original Assignee
マンカインド ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド ファーマ リミテッド filed Critical マンカインド ファーマ リミテッド
Publication of JP2022534510A publication Critical patent/JP2022534510A/ja
Publication of JP2022534510A5 publication Critical patent/JP2022534510A5/ja
Application granted granted Critical
Publication of JP7592029B2 publication Critical patent/JP7592029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021570725A 2019-05-28 2020-05-26 ヤヌスキナーゼ１の阻害のための新規化合物 Active JP7592029B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911021098 2019-05-28
IN201911021098 2019-05-28
PCT/IN2020/050471 WO2020240586A1 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of janus kinase 1

Publications (3)

Publication Number Publication Date
JP2022534510A JP2022534510A (ja) 2022-08-01
JP2022534510A5 JP2022534510A5 (https=) 2024-07-16
JP7592029B2 true JP7592029B2 (ja) 2024-11-29

Family

ID=73553608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570725A Active JP7592029B2 (ja) 2019-05-28 2020-05-26 ヤヌスキナーゼ１の阻害のための新規化合物

Country Status (11)

Country Link
US (1) US12516056B2 (https=)
EP (1) EP3976612A4 (https=)
JP (1) JP7592029B2 (https=)
CN (1) CN114174294B (https=)
AU (1) AU2020284742B2 (https=)
BR (1) BR112021023635A2 (https=)
CA (1) CA3141571A1 (https=)
MX (1) MX2021014361A (https=)
TW (1) TWI839524B (https=)
WO (1) WO2020240586A1 (https=)
ZA (1) ZA202109183B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526521A (ja) * 2020-05-21 2023-06-21 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びそれらの使用
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
PE20250019A1 (es) * 2021-05-06 2025-01-07 Exscientia Ai Ltd MODULADORES DE PKC-theta
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
EP4452944A1 (en) * 2021-12-22 2024-10-30 Icagen, LLC Cyclopropyl compounds
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189617A1 (en) 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
JP2009510161A (ja) 2005-10-03 2009-03-12 アストラゼネカ・アクチエボラーグ 認知症及び神経変性疾患の治療に用いるためのグリコーゲンシンターゼキナーゼ３阻害剤としての新規なイミダゾ「４，５−ｂ］ピリジン誘導体
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
CN105837572A (zh) 2015-02-02 2016-08-10 四川大学 N-取代苯基丙烯酰胺衍生物及其制备方法和用途
CN106146504A (zh) 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
JP2017533897A (ja) 2014-10-06 2017-11-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤としてのヘテロアリール化合物及びその使用
WO2018035080A1 (en) 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
JP2018536634A (ja) 2015-12-11 2018-12-13 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド アゼチジン誘導体、その調製方法、及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
SG10202003901UA (en) * 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
FI124118B (fi) * 2011-06-13 2014-03-31 Reijo Uolevi Hautalahti Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189617A1 (en) 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
JP2009510161A (ja) 2005-10-03 2009-03-12 アストラゼネカ・アクチエボラーグ 認知症及び神経変性疾患の治療に用いるためのグリコーゲンシンターゼキナーゼ３阻害剤としての新規なイミダゾ「４，５−ｂ］ピリジン誘導体
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP2017533897A (ja) 2014-10-06 2017-11-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｂｔｋ阻害剤としてのヘテロアリール化合物及びその使用
CN105837572A (zh) 2015-02-02 2016-08-10 四川大学 N-取代苯基丙烯酰胺衍生物及其制备方法和用途
CN106146504A (zh) 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
JP2018536634A (ja) 2015-12-11 2018-12-13 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド アゼチジン誘導体、その調製方法、及びその使用
WO2018035080A1 (en) 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLOMBANO, G. ET AL，Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease，Journal of Medicinal Chemistry，2019年，62(5)，2447-2465，Supporting Information
SONG, X. ET AL，Imidazopyridines as selective CYP3A4 inhibitors，Bioorganic & Medicinal Chemistry Letters，2012年，22(4)，1611-1614
YNGVE, U. ET AL，Imidazopyridine-Based Inhibitors of Glycogen Synthase Kinase 3: Synthesis and Evaluation of Amide Isostere Replacements of the Carboxamide Scaffold，Chemistry & Biodiversity，2012年，9(11)，2442-2452
インド国特許出願第２３７／ＤＥＬ／２０１４号明細書，2015年07月31日

Also Published As

Publication number Publication date
TW202110838A (zh) 2021-03-16
CA3141571A1 (en) 2020-12-03
ZA202109183B (en) 2022-08-31
EP3976612A4 (en) 2023-04-26
US20220235046A1 (en) 2022-07-28
CN114174294A (zh) 2022-03-11
EP3976612A1 (en) 2022-04-06
CN114174294B (zh) 2024-10-25
MX2021014361A (es) 2022-04-06
AU2020284742B2 (en) 2026-03-05
US12516056B2 (en) 2026-01-06
BR112021023635A2 (pt) 2022-02-01
JP2022534510A (ja) 2022-08-01
AU2020284742A1 (en) 2022-02-03
WO2020240586A1 (en) 2020-12-03
TWI839524B (zh) 2024-04-21

Similar Documents

Publication Publication Date Title
JP7592029B2 (ja) ヤヌスキナーゼ１の阻害のための新規化合物
JP7654643B2 (ja) ホスホジエステラーゼ阻害剤および使用
JP5612573B2 (ja) 新規化学化合物
RU2686117C1 (ru) Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf
KR100883289B1 (ko) 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
RU2269527C2 (ru) Производные пиридопиримидинов, способы их получения и фармацевтическая композиция на их основе
JP6239139B2 (ja) 新規化合物
JP2011528026A6 (ja) 新規化学化合物
JP2009542604A (ja) ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
KR20000068010A (ko) 아졸로 트리아진 및 피리미딘
JP2021500339A (ja) タンパク質キナーゼ阻害剤としての複素環化合物
MXPA06015192A (es) Inhibidores de pirrolotriazina cinasa.
CA2669686A1 (en) 7-substituted purine derivatives for immunosuppression
MXPA02011625A (es) Antagonistas receptores de adenosina a2a.
CN102574860A (zh) 吡咯并[2,3-d]嘧啶化合物
CN102159574A (zh) 三-环吡唑并吡啶激酶抑制剂
KR20230157432A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
US9115149B2 (en) Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
TW202302583A (zh) Ｔｙｋ２抑制劑及其用途
WO2022136914A1 (en) Tyk2 inhibitors and uses thereof
KR20230157431A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
JP4194539B2 (ja) アゾロトリアジン類およびアゾロピリミジン類
RU2833828C2 (ru) Новые соединения для ингибирования янус-киназы 1
CN112047957B (zh) 取代的嘧啶二酮类化合物及其用途
EP2825166A1 (en) Method of treating ophthalmic conditions with kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240704

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241119

R150 Certificate of patent or registration of utility model

Ref document number: 7592029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150